Literature DB >> 28459597

Association of Urinary Activity of MMP-2 with Microalbuminuria in an Isolated Sample of Subjects Living in High Altitude Rural Locations in México.

Magda Elena Hernández-Hernández1, Jaime Morales-Romero2, Clara Luz Sampieri2, Diego Jesús Luna Lozano2, Isidra Del Carmen Valencia Lezama3, Mónica Janett Muñoz Contreras4, Arturo Rodríguez Hernández5.   

Abstract

Hernández-Hernández, Magda Elena, Jaime Morales-Romero, Clara Luz Sampieri, Diego Jesús Luna Lozano, Isidra del Carmen Valencia Lezama, Mónica Janett Muñoz Contreras, and Arturo Rodríguez Hernández. Association of urinary activity of MMP-2 with microalbuminuria in an isolated sample of subjects living in high altitude rural locations in México. High Alt Med Biol. 18:209-218, 2017.-Matrix metalloproteinases (MMP) are implicated in remodeling of the renal extracellular matrix. In a cross-sectional study we evaluated renal impairment in general population of high-altitude rural locations in México. Multivariable analysis was performed to identify the association between MMP-2 and MMP-9 and microalbuminuria. Twenty-eight (20.9%) subjects with renal impairment (WRI) and 106 (79.1%) without renal impairment were included. No differences were found relating to sex, location, marital status, current habits, weight, height, body mass index, waist size in males, creatinine in males, and uric acid. In contrast, differences were found among age, level of education, waist size in general and in females, creatinine in general and in females, urinary albumin, urea, glucose, total cholesterol, and triglycerides. Proportions of hypertension, type 2 diabetes mellitus, central abdominal obesity, hypertriglyceridemia, and hypercholesterolemia were greater in the group WRI. Presence of urinary MMP-2 or of both urinary gelatinases and arbitrary unit (AU) values ≥P90 were associated with microalbuminuria. We conclude that AU values ≥P90 of urinary MMP-2 (OR = 20.1, p = 0.002) is associated with microalbuminuria.

Entities:  

Keywords:  high altitude populations; renal function; urinary matrix metalloproteinases

Mesh:

Substances:

Year:  2017        PMID: 28459597     DOI: 10.1089/ham.2016.0144

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  5 in total

Review 1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature.

Authors:  C L Sampieri; R A Orozco-Ortega
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

2.  Association of urinary activity of MMP-9 with renal impairment in Mexican patients with type 2 diabetes mellitus.

Authors:  Alan Uriel García-Tejeda; Clara Luz Sampieri; Irene Suárez-Torres; Jaime Morales-Romero; Verónica Patricia Demeneghi-Marini; Magda Elena Hernández-Hernández; Arturo Rodríguez-Hernández
Journal:  PeerJ       Date:  2018-12-06       Impact factor: 2.984

3.  Urinary MMP-9/UCr association with albumin concentration and albumin-creatinine-ratio in Mexican patients with type 2 diabetes mellitus.

Authors:  Víctor Gildardo Arcos-Sacramento; Clara Luz Sampieri; Víctor Hugo Sandoval-Lozano; Rubén Arturo Orozco-Ortega; Mariel Alejandra Acuña-Hernández; Jaime Morales-Romero; Magda Elena Hernández-Hernández; Arturo Rodríguez-Hernández
Journal:  PeerJ       Date:  2020-12-16       Impact factor: 2.984

4.  Effect of silibinin on the expression of MMP2, MMP3, MMP9 and TIMP2 in kidney and lung after hepatic ischemia/reperfusion injury in an experimental rat model.

Authors:  Vasileios Kollaras; Georgia Valsami; Maria Lambropoulou; Ourania Konstandi; Nikolaos Kostomistsopoulos; Emmanouil Pikoulis; Constantinos Simopoulos; Alexandra Tsaroucha
Journal:  Acta Cir Bras       Date:  2021-11-08       Impact factor: 1.388

5.  A systematic review of population-based studies on lipid profiles in Latin America and the Caribbean.

Authors:  Rodrigo M Carrillo-Larco; C Joel Benites-Moya; Cecilia Anza-Ramirez; Leonardo Albitres-Flores; Diana Sánchez-Velazco; Niels Pacheco-Barrios; Antonio Bernabe-Ortiz
Journal:  Elife       Date:  2020-08-18       Impact factor: 8.140

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.